Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina

Córdova, Ezequiel; Loiza, Eliana; Porteiro, Norma; Mingrone, Horacio.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 29(6): 428-431, jun.-jul. 2011. ilus, tab
Artigo em Inglês | IBECS (Espanha) | ID: ibc-96817

Documentos relacionados

  1. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
  2. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
  3. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
  4. Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
  5. HIV-1 persistent viremia is frequently followed by episodes of low-level viremia.
  6. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
  7. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients.
  8. Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class.
  9. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.
  10. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.